
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BMD-001
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : $861.0 million
Deal Type : Agreement
Details : Under the agreement, Global Biopharmaceutical will Leverage Biorchestra Targeting Technology Platform, BDDS™ to Develop Nucleic Acid Therapies, including BMD-001, for Treatment of Neurological Disorders in Multiple Targets.
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Undisclosed
March 27, 2023
Lead Product(s) : BMD-001
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : $861.0 million
Deal Type : Agreement

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : BMD-001
Therapeutic Area : Neurology
Study Phase : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : BMD-001 (or BDDS : miR-485-3p ASO) is an antisense oligonucleotides encapsulated with proprietary Brin polymer to cross blood-brain barrier and plasma membrane of microglia, astrocyte and neuron to degrade the microRNA 485-3p and treat neuroinflammation ...
Product Name : Undisclosed
Product Type : Oligonucleotide
Upfront Cash : Inapplicable
June 09, 2022
Lead Product(s) : BMD-001
Therapeutic Area : Neurology
Highest Development Status : Preclinical
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Study Phase : Discovery
Sponsor : SK Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
SK Biopharmaceuticals, BIORCHESTRA Collaborate to Develop miRNA-Targeted Therapeutics
Details : Under the collaboration agreement, BIORCHESTRA, that develops RNA therapeutics for neurodegenerative diseases, will be responsible for target discovery, selection, and synthesis via its in-house technology by using antisense oligonucleotides.
Product Name : Undisclosed
Product Type : Undisclosed
Upfront Cash : Undisclosed
January 05, 2022
Lead Product(s) : Undisclosed
Therapeutic Area : Neurology
Highest Development Status : Discovery
Sponsor : SK Biopharmaceuticals
Deal Size : Undisclosed
Deal Type : Collaboration
